Logo image
Improved NYVAC-Based Vaccine Vectors
Journal article   Open access   Peer reviewed

Improved NYVAC-Based Vaccine Vectors

Karen V. Kibler, Carmen E. Gomez, Beatriz Perdiguero, Shukmei Wong, Trung Huynh, Susan Holechek, William Arndt, Victoria Jimenez, Ruben Gonzalez-Sanz, Karen Denzler, …
PloS one, v 6(11), pp e25674-e25674
09 Nov 2011
PMID: 22096477
url
https://doi.org/10.1371/journal.pone.0025674View
Published, Version of Record (VoR) Open

Abstract

Biology
While as yet there is no vaccine against HIV/AIDS, the results of the phase III Thai trial (RV144) have been encouraging and suggest that further improvements of the prime/boost vaccine combination of a poxvirus and protein are needed. With this aim, in this investigation we have generated derivatives of the candidate vaccinia virus vaccine vector NYVAC with potentially improved functions. This has been achieved by the re-incorporation into the virus genome of two host range genes, K1L and C7L , in conjunction with the removal of the immunomodulatory viral molecule B19, an antagonist of type I interferon action. These novel virus vectors, referred to as NYVAC-C-KC and NYVAC-C-KC-ΔB19R, have acquired relevant biological characteristics, giving higher levels of antigen expression in infected cells, replication-competency in human keratinocytes and dermal fibroblasts, activation of selective host cell signal transduction pathways, and limited virus spread in tissues. Importantly, these replication-competent viruses have been demonstrated to maintain a highly attenuated phenotype.

Metrics

5 Record Views
61 citations in Scopus

Details

UN Sustainable Development Goals (SDGs)

This publication has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

InCites Highlights

Data related to this publication, from InCites Benchmarking & Analytics tool:

Collaboration types
Industry collaboration
Domestic collaboration
International collaboration
Web of Science research areas
Virology
Logo image